The drug in question has an interesting storyline. It was developed by the same guys who developed MDVN's PC drug, and is almost identical to XTANDI. MDVN thought they had licensed the existing candidates, and had a right of first refusal on others, but the researchers hid a couple.
thanks Fib, it's good to hear you are still with us. It's been slow on the IMGN MB and with the stock price/volume. Not much new interest it seems. I ran into a key person who seemed excited about another new compound entering the clinic this year, maybe we will hear more about that soon, not that a new molecule will have much effect on the stock price.